<DOC>
	<DOCNO>NCT01626339</DOCNO>
	<brief_summary>Patients schedule intravitreal injection Ranibizumab Bevacizumab recruit prospective self-controlled trial . Fundus photography carry baseline immediately injection 3 , 7 day 30 day first injection . Using image analysis software , measurement summarize central retinal artery equivalent ( CRAE ) central retinal vein equivalent ( CRVE ) . Null Hypothesis : There significant difference arteriolar/venular diameter injection intravitreal ranibizumab/bevacizumab treat untreated eye</brief_summary>
	<brief_title>Effect Intravitreal Anti-VEGF Retinal Vessels Diameter</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>• Patients wish need bevacizumab ranibizumab treatment underlying disease History previous systemic ocular AntiVEGF therapy History previous intravitreal injection drug Intraocular pressure ≥ 22 Glaucoma History presence thromboembolic event Uncontrolled blood pressure Blood donation previous 3 week Relevant medium opacity lens</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Anti vascular endothelial growth factor</keyword>
	<keyword>retinal vessel</keyword>
</DOC>